Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 5Neoplasms 3Fallopian Tube Neoplasms 2Urinary Bladder Neoplasms 1Skin Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Carcinogenesis 1Brain Neoplasms 1

Interventions

Nivolumab 13Ipilimumab 10pembrolizumab 8cemiplimab 6Surveys and Questionnaires 6Biopsy 6aldesleukin 5Radiotherapy 5Interleukin-2 5Blood Specimen Collection 5Temozolomide 4Sirolimus 4Photochemotherapy 4Mohs Surgery 4HhAntag691 4Fluorouracil 4Educational Status 4Cyclophosphamide 4sonidegib 3fludarabine phosphate 3fludarabine 3avelumab 3Vemurafenib 3Surgical Procedures, Operative 3Radiation 3Petrolatum 3Cetuximab 3Aminolevulinic Acid 3trametinib 2dabrafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Skin Neoplasms × Monatide (IMS 3015) × Clear all
NCT01079741 2018-02-13

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
34 enrolled 10 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms, Carcinogenesis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡